Osteoarthritic Pain – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
More than 30 million people in the United States are afflicted with osteoarthritic (OA) pain; we expect an aging population and the increasing prevalence of obesity to drive further growth. Although a wide array of medications is used to treat OA pain, including nonsteroidal anti-inflammatory drugs (NSAIDs), antidepressants, antiepileptic drugs (AEDs), and intra-articular agents, unmet need exists for novel, comprehensively effective, and tolerable alternatives. The successful launch of a novel analgesic requires a granular understanding of treatment patterns in this crowded and highly generic market.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed OA pain patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed OA pain patients?
- How have branded agents offering incremental safety, tolerability, or dosing benefits fared in this highly generic market, where cost-effectiveness is a primary driver of coverage?
- How has Flexion Therapeutics’ Zilretta been integrated into the treatment algorithm, and what is its source of business?
- What percentage of OA pain patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of OA pain patients are treated with monotherapy vs. combination therapy? What are the most used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States.
Key companies: Flexion Therapeutics, Collegium Pharmaceuticals, Protega Pharmaceuticals, Averitas Pharma, Kowa.
Key drugs: Zilretta, injectable corticosteroids, injectable hyaluronic acid preparations, oral and topical NSAIDs, antidepressants, AEDs (e.g., gabapentin), opioid analgesics (e.g., Belbuca, RoxyBond, Xtampza ER), Qutenza, Seglentis.
Solution enhancement
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.
Table of contents
- Osteoarthritic Pain - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
- Treatment Algorithms CDA Osteoarthritic Pain US May 2023
- Treatment Algorithms CDA Osteoarthritic Pain 2023 Dashboard
John Crowley, Ph.D., is the principal director of the Infectious, Niche, & Rare Diseases team at DRG, part of Clarivate. Prior to his current role, he was a director on the team overseeing syndicated and custom work on niche and rare disease markets, as well as atopic dermatitis content in DRG’s Dermatology portfolio. He also served as a DRG analyst in the neurology space, focused mainly on the multiple sclerosis market. Dr. Crowley holds a Ph.D. from the University of Massachusetts Medical School and a bachelor’s degree from Worcester Polytechnic Institute.